Developer docs
API playgroundTry for free, no card

Search company profiles

GRIN Therapeutics

Full company profile

uuid0000asm

Namestring
GRIN Therapeutics
Legal namestring
GRIN Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

GRIN Therapeutics, Inc. is a clinical-stage biotechnology company developing precision therapeutics for rare, severe pediatric neurodevelopmental disorders. Founded in 2019 by Dr. Pierandrea Muglia after engagement with the GRIN patient community at the CFERV Conference on GRIN Variants at Emory University, the company is headquartered in New York City (230 Park Avenue, Suite 2830) and operates as an affiliate of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company. The company focuses on a single core asset, radiprodil, an investigational orally bioavailable selective negative allosteric modulator (NAM) of the GluN2B (NR2B) subunit of the NMDA receptor, which addresses dysregulated NMDA receptor activity underlying multiple genetically defined neurodevelopmental conditions.

Radiprodil is being developed for three indications: GRIN-related neurodevelopmental disorder (GRIN-NDD) caused by gain-of-function variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D genes; tuberous sclerosis complex (TSC); and focal cortical dysplasia type II (FCDII). The company is running three concurrent clinical programs: the Phase 3 Beeline pivotal trial in GRIN-NDD (first patient dosed January 2026 with global sites in the US, UK, and Europe through May 2026), the Phase 1b/2a Astroscape trial in TSC/FCDII (initiated October 2024), and an observational natural history study for GRIN-NDD. The Phase 1b/2a Honeycomb trial reported a median 86% reduction in countable motor seizure frequency in 15 patients with gain-of-function GRIN variants, supporting advancement to Phase 3. Radiprodil has received FDA Breakthrough Therapy, FDA Orphan Drug, FDA Rare Pediatric Disease, EMA PRIME, and EMA Orphan Drug designations.

GRIN Therapeutics is currently pre-revenue, with a forward revenue model dependent on pharmaceutical product sales following regulatory approval, supplemented by licensing arrangements. In May 2025, the company closed a $140 million Series D round co-led by Blackstone Life Sciences and Angelini Pharma, concurrently entering an exclusive licensing agreement with Angelini Pharma for radiprodil development and commercialization outside North America, with $50 million upfront and potential total deal value exceeding $500 million. The company operates with 11-50 employees, engages patients and providers primarily through patient advocacy partnerships (GRIN2B Foundation, CureGRIN, TSC Alliance, Epilepsy Foundation), trial recruitment and genetic testing partners (InformedDNA, GeneDx, Broad Institute GRIN Portal), and scientific congresses including AES and ILAE.

Short descriptiontext

GRIN Therapeutics is a clinical-stage biotechnology company developing radiprodil, an oral selective GluN2B NMDA receptor negative allosteric modulator, for rare pediatric neurodevelopmental disorders including GRIN-NDD, tuberous sclerosis complex, and focal cortical dysplasia type II.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, neurodevelopmental disorder treatments, NMDA receptor modulators, pediatric epilepsy therapies, precision medicine biotechnology
Industry2 codes
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Rare Pediatric Neurodevelopmental Disorder Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

GRIN Therapeutics is a clinical-stage biotechnology company developing radiprodil for rare neurodevelopmental disorders. Revenue will be generated through product sales following regulatory approval. The company secured $140 million in Series D funding and entered a licensing agreement with Angelini Pharma worth over $500 million in potential future payments for development and commercialization rights outside North America.

endpts.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Honeycomb Trial
Description

Phase 1b/2a clinical trial evaluating radiprodil in GRIN-NDD patients with gain-of-function variants.

grintherapeutics.com
+2 more records
Core offering1 text field

GRIN Therapeutics is developing radiprodil, an investigational orally bioavailable selective negative allosteric modulator of the GluN2B (NR2B) subunit of the NMDA receptor, for the treatment of rare pediatric neurodevelopmental disorders including GRIN-related neurodevelopmental disorder (GRIN-NDD) with gain-of-function variants, tuberous sclerosis complex (TSC), and focal cortical dysplasia type II (FCDII). The company is advancing radiprodil through a global Phase 3 clinical program (Beeline) supplemented by additional clinical studies (Honeycomb, Astroscape) and a natural history study, with future commercialization planned through specialty rare-disease pharmaceutical channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Median 86% reduction in countable motor seizure frequency in Phase 1b/2a Honeycomb trial patients with gain-of-function variants
+1 more record
Product overview1 text field

GRIN Therapeutics is a clinical-stage biotechnology company developing a single core pharmaceutical product, radiprodil, an investigational negative allosteric modulator of the GluN2B NMDA receptor subunit. The company operates multiple clinical trial programs including the Phase 3 Beeline trial for GRIN-NDD, the Phase 1b/2a Honeycomb trial (completed), the Phase 1b/2a Astroscape trial for TSC and FCDII, and an observational Natural History Study for GRIN-NDD. The company does not offer a software platform or module-based products.

Product and service1 record
1Radiprodil
CategoryInvestigational small-molecule pharmaceutical (NMDA receptor negative allosteric modulator)
Description

Investigational, orally bioavailable, selective negative allosteric modulator (NAM) of the GluN2B (NR2B) subunit of the NMDA receptor. Developed for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD) with gain-of-function variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D, tuberous sclerosis complex (TSC), and focal cortical dysplasia type II (FCDII). It modulates excessive NMDA receptor activity without fully inhibiting the channel, targeting the underlying pathological mechanism rather than just symptoms.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-05-27
Description

Angelini Pharma entered into an exclusive licensing agreement with GRIN Therapeutics for the development and commercialization of radiprodil outside North America. Angelini Pharma paid $50 million upfront as part of the agreement, with potential total deal value exceeding $500 million in future payments. The partnership covers multiple neurodevelopmental disorders including GRIN-NDD, TSC, and FCDII.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

InformedDNA serves as GRIN Therapeutics' partner for clinical trial recruiting and genetic counseling services specifically for patients with GRIN-NDD in the United States. The partnership helps route patients to genetic variant characterization and clinical trial opportunities.

Strategic tierCoreTypeTechnology or Integration
Description

GRIN Therapeutics works with the Broad Institute's GRIN Portal, which allows patients diagnosed with GRIN-NDD to explore information about their specific GRIN variant. This resource supports variant characterization for clinical trial eligibility.

4CureSHANK
Strategic tierMinorTypeStrategic or Co-development Partner
Description

GRIN Therapeutics is a supporting sponsor of CureSHANK's Genetic Testing Action Day initiative, supporting efforts to raise awareness about genetic testing for patients with rare diseases and developmental disabilities.

prnewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Epygenix Therapeutics
TypeEmerging player
Description

Emerging clinical-stage biotech developing precision therapies for rare epilepsies including Dravet syndrome and Lennox-Gastaut syndrome. Comparable as an early-stage rare epilepsy player focused on genetically defined populations.

TypeBroad incumbent
Description

Global pharmaceutical company specializing in brain diseases including rare neurology. Relevant given Board Chair Deborah Dunsire's prior leadership; represents a strategic potential acquirer or partner for radiprodil given deep rare neurology commercial capabilities.

TypeDirect peer
Description

Develops ganaxolone for rare seizure disorders including CDKL5 deficiency disorder and tuberous sclerosis complex. Directly comparable given its focus on rare pediatric epilepsies and overlapping TSC indication with radiprodil.

TypeBroad incumbent
Description

Established rare disease biopharma with multiple orphan therapies on market. Comparable as a scaled rare disease commercial model with experience launching and pricing orphan therapeutics across geographies.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on monogenic rare diseases of the central nervous system. Comparable target patient profile (rare genetic neurodevelopmental disorders) and development-stage risk profile.

TypeBroad incumbent
Description

Specialty pharmaceutical company with a significant rare neurology franchise including Epidiolex for rare epilepsies. Comparable as an established player in rare pediatric neurology commercialization that could compete or partner in the same end markets.

TypeDirect peer
Description

Clinical-stage precision medicine company developing therapies for genetic epilepsies and CNS disorders. Comparable in approach (genetically defined rare CNS populations) and stage of clinical development.

TypeDirect peer
Description

Develops antisense oligonucleotide (ASO) therapies for genetic diseases including Dravet syndrome and other rare neurodevelopmental disorders. Comparable as a rare pediatric neuro precision medicine company with mechanism-driven development.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics for rare neurodevelopmental disorders including CDKL5 deficiency disorder and Angelman syndrome. Directly comparable as a rare pediatric neurology-focused biotech with similar development-stage assets and patient advocacy-driven strategy.

TypeBroad incumbent
Description

Global biopharma with a rare epilepsy franchise built around Fintepla (fenfluramine) for Dravet and Lennox-Gastaut syndromes following the Zogenix acquisition. Comparable as a major incumbent commercializing rare pediatric epilepsy therapies that overlap with GRIN's TSC and FCDII target populations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GRIN Therapeutics

Rare Pediatric Neurodevelopmental Disorder Therapeuticsgrintherapeutics.com

GRIN Therapeutics is a clinical-stage biotechnology company developing radiprodil, an oral selective GluN2B NMDA receptor negative allosteric modulator, for rare pediatric neurodevelopmental disorders including GRIN-NDD, tuberous sclerosis complex, and focal cortical dysplasia type II.

What GRIN Therapeutics does

GRIN Therapeutics, Inc. is a clinical-stage biotechnology company developing precision therapeutics for rare, severe pediatric neurodevelopmental disorders. Founded in 2019 by Dr. Pierandrea Muglia after engagement with the GRIN patient community at the CFERV Conference on GRIN Variants at Emory University, the company is headquartered in New York City (230 Park Avenue, Suite 2830) and operates as an affiliate of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company. The company focuses on a single core asset, radiprodil, an investigational orally bioavailable selective negative allosteric modulator (NAM) of the GluN2B (NR2B) subunit of the NMDA receptor, which addresses dysregulated NMDA receptor activity underlying multiple genetically defined neurodevelopmental conditions.

Radiprodil is being developed for three indications: GRIN-related neurodevelopmental disorder (GRIN-NDD) caused by gain-of-function variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D genes; tuberous sclerosis complex (TSC); and focal cortical dysplasia type II (FCDII). The company is running three concurrent clinical programs: the Phase 3 Beeline pivotal trial in GRIN-NDD (first patient dosed January 2026 with global sites in the US, UK, and Europe through May 2026), the Phase 1b/2a Astroscape trial in TSC/FCDII (initiated October 2024), and an observational natural history study for GRIN-NDD. The Phase 1b/2a Honeycomb trial reported a median 86% reduction in countable motor seizure frequency in 15 patients with gain-of-function GRIN variants, supporting advancement to Phase 3. Radiprodil has received FDA Breakthrough Therapy, FDA Orphan Drug, FDA Rare Pediatric Disease, EMA PRIME, and EMA Orphan Drug designations.

GRIN Therapeutics is currently pre-revenue, with a forward revenue model dependent on pharmaceutical product sales following regulatory approval, supplemented by licensing arrangements. In May 2025, the company closed a $140 million Series D round co-led by Blackstone Life Sciences and Angelini Pharma, concurrently entering an exclusive licensing agreement with Angelini Pharma for radiprodil development and commercialization outside North America, with $50 million upfront and potential total deal value exceeding $500 million. The company operates with 11-50 employees, engages patients and providers primarily through patient advocacy partnerships (GRIN2B Foundation, CureGRIN, TSC Alliance, Epilepsy Foundation), trial recruitment and genetic testing partners (InformedDNA, GeneDx, Broad Institute GRIN Portal), and scientific congresses including AES and ILAE.

GRIN Therapeutics firmographics

Firmographics
Name
GRIN Therapeutics
Legal name
GRIN Therapeutics, Inc.
Website
https://grintherapeutics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
GRIN Therapeutics is a clinical-stage biotechnology company developing radiprodil, an oral selective GluN2B NMDA receptor negative allosteric modulator, for rare pediatric neurodevelopmental disorders including GRIN-NDD, tuberous sclerosis complex, and focal cortical dysplasia type II.
Ownership category
akta.pro rank

GRIN Therapeutics industry classification

Industry
Product category
Rare Pediatric Neurodevelopmental Disorder Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Neurodevelopmental disorder treatments
  • NMDA receptor modulators
  • Pediatric epilepsy therapies
  • Precision medicine biotechnology

Where GRIN Therapeutics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

GRIN Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Development and Commercialization: GRIN Therapeutics is a clinical-stage biotechnology company developing radiprodil for rare neurodevelopmental disorders. Revenue will be generated through product sales following regulatory approval. The company secured $140 million in Series D funding and entered a licensing agreement with Angelini Pharma worth over $500 million in potential future payments for development and commercialization rights outside North America.

Go-to-market motion1 record

Marketing channels4 records

GRIN Therapeutics product offering

Product offering

Core offering

GRIN Therapeutics is developing radiprodil, an investigational orally bioavailable selective negative allosteric modulator of the GluN2B (NR2B) subunit of the NMDA receptor, for the treatment of rare pediatric neurodevelopmental disorders including GRIN-related neurodevelopmental disorder (GRIN-NDD) with gain-of-function variants, tuberous sclerosis complex (TSC), and focal cortical dysplasia type II (FCDII). The company is advancing radiprodil through a global Phase 3 clinical program (Beeline) supplemented by additional clinical studies (Honeycomb, Astroscape) and a natural history study, with future commercialization planned through specialty rare-disease pharmaceutical channels.

Product overview

GRIN Therapeutics is a clinical-stage biotechnology company developing a single core pharmaceutical product, radiprodil, an investigational negative allosteric modulator of the GluN2B NMDA receptor subunit. The company operates multiple clinical trial programs including the Phase 3 Beeline trial for GRIN-NDD, the Phase 1b/2a Honeycomb trial (completed), the Phase 1b/2a Astroscape trial for TSC and FCDII, and an observational Natural History Study for GRIN-NDD. The company does not offer a software platform or module-based products.

Differentiator

Problem solved

Functional benefit

Brands

  • Honeycomb Trial: Phase 1b/2a clinical trial evaluating radiprodil in GRIN-NDD patients with gain-of-function variants.
  • Beeline Trial
  • Astroscape Trial

Products and services

  • Radiprodil Investigational, orally bioavailable, selective negative allosteric modulator (NAM) of the GluN2B (NR2B) subunit of the NMDA receptor. Developed for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD) with gain-of-function variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D, tuberous sclerosis complex (TSC), and focal cortical dysplasia type II (FCDII). It modulates excessive NMDA receptor activity without fully inhibiting the channel, targeting the underlying pathological mechanism rather than just symptoms.

Quantifiable outcome

  • Median 86% reduction in countable motor seizure frequency in Phase 1b/2a Honeycomb trial patients with gain-of-function variants
  • +1 more outcomes

Companies that use GRIN Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

GRIN Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

GRIN Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

  • Angelini PharmaflagshipOEM/ Whitelabel/ Licensing Partner · 27 May 2025Angelini Pharma entered into an exclusive licensing agreement with GRIN Therapeutics for the development and commercialization of radiprodil outside North America. Angelini Pharma paid $50 million upfront as part of the agreement, with potential total deal value exceeding $500 million in future payments. The partnership covers multiple neurodevelopmental disorders including GRIN-NDD, TSC, and FCDII.
  • InformedDNAcoreStrategic or Co-development PartnerInformedDNA serves as GRIN Therapeutics' partner for clinical trial recruiting and genetic counseling services specifically for patients with GRIN-NDD in the United States. The partnership helps route patients to genetic variant characterization and clinical trial opportunities.
  • Broad Institute (GRIN Portal)coreTechnology or IntegrationGRIN Therapeutics works with the Broad Institute's GRIN Portal, which allows patients diagnosed with GRIN-NDD to explore information about their specific GRIN variant. This resource supports variant characterization for clinical trial eligibility.
  • CureSHANKminorStrategic or Co-development PartnerGRIN Therapeutics is a supporting sponsor of CureSHANK's Genetic Testing Action Day initiative, supporting efforts to raise awareness about genetic testing for patients with rare diseases and developmental disabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

GRIN Therapeutics competitors and assessment

Company assessment

Emerging players

  • Epygenix Therapeutics: Emerging clinical-stage biotech developing precision therapies for rare epilepsies including Dravet syndrome and Lennox-Gastaut syndrome. Comparable as an early-stage rare epilepsy player focused on genetically defined populations.

Broad incumbents

  • Lundbeck: Global pharmaceutical company specializing in brain diseases including rare neurology. Relevant given Board Chair Deborah Dunsire's prior leadership; represents a strategic potential acquirer or partner for radiprodil given deep rare neurology commercial capabilities.
  • BioMarin Pharmaceutical: Established rare disease biopharma with multiple orphan therapies on market. Comparable as a scaled rare disease commercial model with experience launching and pricing orphan therapeutics across geographies.
  • Jazz Pharmaceuticals: Specialty pharmaceutical company with a significant rare neurology franchise including Epidiolex for rare epilepsies. Comparable as an established player in rare pediatric neurology commercialization that could compete or partner in the same end markets.
  • UCB (Zogenix): Global biopharma with a rare epilepsy franchise built around Fintepla (fenfluramine) for Dravet and Lennox-Gastaut syndromes following the Zogenix acquisition. Comparable as a major incumbent commercializing rare pediatric epilepsy therapies that overlap with GRIN's TSC and FCDII target populations.

Direct peers

  • Marinus Pharmaceuticals: Develops ganaxolone for rare seizure disorders including CDKL5 deficiency disorder and tuberous sclerosis complex. Directly comparable given its focus on rare pediatric epilepsies and overlapping TSC indication with radiprodil.
  • Taysha Gene Therapies: Clinical-stage gene therapy company focused on monogenic rare diseases of the central nervous system. Comparable target patient profile (rare genetic neurodevelopmental disorders) and development-stage risk profile.
  • Praxis Precision Medicines: Clinical-stage precision medicine company developing therapies for genetic epilepsies and CNS disorders. Comparable in approach (genetically defined rare CNS populations) and stage of clinical development.
  • Stoke Therapeutics: Develops antisense oligonucleotide (ASO) therapies for genetic diseases including Dravet syndrome and other rare neurodevelopmental disorders. Comparable as a rare pediatric neuro precision medicine company with mechanism-driven development.
  • Ovid Therapeutics: Clinical-stage biotech developing therapeutics for rare neurodevelopmental disorders including CDKL5 deficiency disorder and Angelman syndrome. Directly comparable as a rare pediatric neurology-focused biotech with similar development-stage assets and patient advocacy-driven strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

GRIN Therapeutics social profiles

Digital presence

GRIN Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GRIN Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

GRIN Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GRIN Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GRIN Therapeutics

What does GRIN Therapeutics do?

GRIN Therapeutics is developing radiprodil, an investigational orally bioavailable selective negative allosteric modulator of the GluN2B (NR2B) subunit of the NMDA receptor, for the treatment of rare pediatric neurodevelopmental disorders including GRIN-related neurodevelopmental disorder (GRIN-NDD) with gain-of-function variants, tuberous sclerosis complex (TSC), and focal cortical dysplasia type II (FCDII). The company is advancing radiprodil through a global Phase 3 clinical program (Beeline) supplemented by additional clinical studies (Honeycomb, Astroscape) and a natural history study, with future commercialization planned through specialty rare-disease pharmaceutical channels.

Is GRIN Therapeutics a public or private company?

GRIN Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was GRIN Therapeutics founded?

GRIN Therapeutics was founded in 2019. It employs 1 to 10 people.

Where is GRIN Therapeutics based?

GRIN Therapeutics is headquartered in New York, United States, in the North America region.

How does GRIN Therapeutics make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are GRIN Therapeutics's main competitors?

Epygenix Therapeutics is listed as an emerging player. Broad incumbents are Lundbeck, BioMarin Pharmaceutical, Jazz Pharmaceuticals and UCB (Zogenix). Direct peers are Marinus Pharmaceuticals, Taysha Gene Therapies, Praxis Precision Medicines, Stoke Therapeutics and Ovid Therapeutics.

Does GRIN Therapeutics have an API?

No public API is recorded for GRIN Therapeutics.

What industry is GRIN Therapeutics in?

GRIN Therapeutics's product category is Rare Pediatric Neurodevelopmental Disorder Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pharmaphorumGRIN Therapeutics: Seeking to address unmet needs in rare neurodevelopmental disordersGRIN Therapeutics raised $140 million in a Series D and secured a $570 million licensing deal with Angelini Pharma. The company is developing radiprodil, an NMDA modulator, after showing encouraging results in a Phase 1b trial. It plans to launch a pivotal Phase 3 trial for GRIN-related neurodevelopmental disorders.European BiotechnologyHow biotech is treating epilepsy beyond seizuresEpilepsy treatment is shifting from broad seizure suppression to targeted therapies addressing underlying biological causes. Neurona's cell therapy rezanecel and Stoke's antisense drug zorevunersen aim to restore inhibitory circuits or correct genetic defects. Precision treatments require genetic testing, and the field expects more personalized approaches.PR NewswireNeurvati Neurosciences Strengthens Executive Leadership Team to Advance Next Phase of Growth at GRIN TherapeuticsNeurvati Neurosciences appointed J. Michael Ryan as Chief Medical Officer and promoted Anne-Marie Li-Kwai-Cheung to Chief Development Officer and Elliott Ruiz to Chief Financial Officer. The appointments support GRIN Therapeutics' global Phase 3 Beeline study of radiprodil for GRIN-related neurodevelopmental disorder and its Phase 1b/2a Astroscape study. The leadership changes position Neurvati to expand its neuroscience development platform through future affiliate companies.PR NewswireStart Genetic Announces Second Annual Genetic Testing Action Day on July 25, 2026Start Genetic announced the second annual Genetic Testing Action Day, scheduled for July 25, 2026, to raise awareness about the role of genetic testing in helping patients with rare diseases, developmental disabilities, and other conditions obtain diagnoses. A recent Medicaid claims analysis cited in the announcement found that only 16.9% of children with autism receive genetic testing despite longstanding recommendations supporting such evaluation. The campaign is supported by sponsors including Illumina, PYC Therapeutics, Neuren Pharmaceuticals, GRIN Therapeutics, Jaguar Gene Therapy, and MyOme, and operates as an initiative of nonprofit CureSHANK.PR NewswireGRIN Therapeutics' Pivotal Phase 3 Beeline Study Initiated in EuropeGRIN Therapeutics announced the initiation of its pivotal Phase 3 Beeline study in Europe, expanding the global registrational trial for investigational radiprodil to treat GRIN-related neurodevelopmental disorder (GRIN-NDD). The European activation includes sites in Belgium, France, Germany, Italy, Poland, the Netherlands, Slovenia, and Spain, augmenting enrollment already underway in the United States and United Kingdom. The trial builds on Phase 1b/2a Honeycomb study data showing a median 86% reduction in seizure frequency in patients with countable motor seizures, with further EU country activations anticipated in September 2026.BioSpaceGRIN Therapeutics’ Pivotal Phase 3 Beeline Study Initiated in EuropeGRIN Therapeutics initiated its Phase 3 Beeline study in Europe, expanding the global trial for radiprodil in GRIN-related neurodevelopmental disorder. The trial builds on Phase 1b/2a data showing an 86% median reduction in motor seizures. European sites are expected to come online in September 2026.PR NewswireGRIN Therapeutics to Present on Global Phase 3 Beeline Clinical Trial of Radiprodil at American Epilepsy Society Annual MeetingGRIN Therapeutics announced it will present data on novel clinical outcome scales for GRIN-related neurodevelopmental disorder at the American Epilepsy Society Annual Meeting. These scales are designed to evaluate the investigational therapy radiprodil in its upcoming global Phase 3 Beeline clinical trial. The presentation highlights methodologies for measuring seizures and behavioral changes, building on promising Phase 1b/2a data that prompted the advancement to pivotal trials.The Medicine MakerThe Biosimulation GenerationThe article discusses the shift towards AI-driven biosimulation in pharmaceutical research and development as the FDA moves to phase out mandatory animal testing. Certara, collaborating with GRIN Therapeutics, is highlighted for their development of a PBPK model to assist in dosing for pediatric epilepsy, showcasing the practical implications of biosimulation in clinical settings. The emergence of these technologies raises questions about regulatory acceptance and the future of drug development practices.SilverwoodpartnersHealthcare Private Placement and M&A Transactions Review Week Ending June 1, 2025Neuralink raised $650 million in Series E funding, with participation from G42, Lightspeed Commerce, and Valor Equity Partners, valuing the company at $8.4 billion as of May 27, 2025. Several other companies, including Jane and GRIN Therapeutics, also announced significant venture funding transactions during the same week. The article reviews multiple healthcare-related private placements and M&A activities for the week ending June 1, 2025.Phirda9家创新药公司完成新一轮融资!Nine biotech companies completed new financing rounds in May 2025, including Vima Therapeutics, GRIN Therapeutics, and GlycoEra. Funding ranged from €1.4 million to $130 million, with products targeting diseases like cancer, neurological disorders, and autoimmune conditions. The capital will support clinical trials and platform development.